Minu K. Srivastava

2.8k total citations · 2 hit papers
52 papers, 2.0k citations indexed

About

Minu K. Srivastava is a scholar working on Immunology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Minu K. Srivastava has authored 52 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Immunology, 26 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Minu K. Srivastava's work include Immunotherapy and Immune Responses (23 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Immune Cell Function and Interaction (11 papers). Minu K. Srivastava is often cited by papers focused on Immunotherapy and Immune Responses (23 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Immune Cell Function and Interaction (11 papers). Minu K. Srivastava collaborates with scholars based in United States, Germany and Italy. Minu K. Srivastava's co-authors include Suzanne Ostrand‐Rosenberg, Virginia K. Clements, Paulo C. Rodrı́guez, Pratima Sinha, Sherven Sharma, Steven M. Dubinett, Marni E. Harris‐White, Jay M. Lee, Li Zhu and Jacobus J. Bosch and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Minu K. Srivastava

46 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine

2009 759 citations Minu K. Srivastava, Pratima Sinha et al. Cancer Research profile →
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

2023 126 citations Enriqueta Felip, Nasser K. Altorki et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Minu K. Srivastava United States	18	1.3k	960	480	238	209	52	2.0k
Isabel Poschke Germany	27	2.1k 1.6×	1.5k 1.6×	573 1.2×	106 0.4×	145 0.7×	49	2.7k
Nesrine I. Affara United States	12	1.4k 1.1×	1.2k 1.3×	681 1.4×	160 0.7×	420 2.0×	14	2.3k
Monther Al‐Alwan Saudi Arabia	22	840 0.6×	823 0.9×	626 1.3×	156 0.7×	217 1.0×	46	1.8k
Yan Lan United States	19	782 0.6×	922 1.0×	624 1.3×	109 0.5×	117 0.6×	34	1.8k
Swetha Anandhan United States	9	899 0.7×	951 1.0×	612 1.3×	209 0.9×	202 1.0×	13	1.8k
Amira Barkal United States	9	1.2k 0.9×	544 0.6×	939 2.0×	128 0.5×	188 0.9×	11	2.0k
Maxim Markovic United States	6	1.2k 0.9×	482 0.5×	558 1.2×	109 0.5×	154 0.7×	7	1.6k
Yogesh Dhungana United States	18	1.2k 0.9×	584 0.6×	773 1.6×	103 0.4×	357 1.7×	27	1.9k
Mario Di Matteo Belgium	15	745 0.6×	481 0.5×	803 1.7×	94 0.4×	335 1.6×	20	1.6k
Indira Krishnan United States	11	786 0.6×	501 0.5×	757 1.6×	119 0.5×	255 1.2×	23	1.5k

Countries citing papers authored by Minu K. Srivastava

Since Specialization

Citations

This map shows the geographic impact of Minu K. Srivastava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minu K. Srivastava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minu K. Srivastava more than expected).

Fields of papers citing papers by Minu K. Srivastava

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minu K. Srivastava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minu K. Srivastava. The network helps show where Minu K. Srivastava may publish in the future.

Co-authorship network of co-authors of Minu K. Srivastava

This figure shows the co-authorship network connecting the top 25 collaborators of Minu K. Srivastava. A scholar is included among the top collaborators of Minu K. Srivastava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minu K. Srivastava. Minu K. Srivastava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lu, Tianshi, Habib Hamidi, Mark A. Socinski, et al.. (2025). Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. Nature Communications. 17(1). 122–122.

Srivastava, Minu K., Wei Zou, Mark L. McCleland, et al.. (2025). Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel. Journal for ImmunoTherapy of Cancer. 13(5). e010578–e010578.

Wakelee, Heather A., Nasser K. Altorki, Caicun Zhou, et al.. (2024). IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(17_suppl). LBA8035–LBA8035. 6 indexed citations

Şenbabaoğlu, Yasin, Aminollah Khormali, Elisa Warner, et al.. (2024). MOSBY enables multi-omic inference and spatial biomarker discovery from whole slide images. Scientific Reports. 14(1). 18271–18271. 2 indexed citations

Pellini, Bruna, Russell W. Madison, Ole Gjoerup, et al.. (2023). Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(22). 4596–4605. 25 indexed citations

Felip, Enriqueta, Nasser K. Altorki, Caicun Zhou, et al.. (2023). Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Annals of Oncology. 34(10). 907–919. 126 indexed citations breakdown →

Srivastava, Minu K., et al.. (2023). 527 Clonal hematopoiesis is associated with reduced response to immune checkpoint inhibitors in lung cancer. SHILAP Revista de lepidopterología. A598–A599. 1 indexed citations

Srivastava, Minu K., Velimir Gayevskiy, Ivette Estay, et al.. (2023). 606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy. SHILAP Revista de lepidopterología. A690–A690. 3 indexed citations

Filbert, Erin L., et al.. (2021). APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunology Immunotherapy. 70(7). 1853–1865. 22 indexed citations

10.

Vences‐Catalán, Felipe, Ranjani Rajapaksa, Minu K. Srivastava, et al.. (2015). Tetraspanin CD81 Promotes Tumor Growth and Metastasis by Modulating the Functions of T Regulatory and Myeloid-Derived Suppressor Cells. Cancer Research. 75(21). 4517–4526. 67 indexed citations

11.

Srivastava, Minu K., Christopher L. Murriel, Julie M. Roda, et al.. (2015). Abstract 255: Dual targeting of Delta-like ligand 4 (DLL4) and programmed death 1(PD1) inhibits tumor growth and generates enhanced long-term immunological memory. Cancer Research. 75(15_Supplement). 255–255. 1 indexed citations

12.

Zhu, Li, Minu K. Srivastava, Puja Kachroo, et al.. (2015). GITR agonist enhances vaccination responses in lung cancer. OncoImmunology. 4(4). e992237–e992237. 17 indexed citations

13.

Srivastava, Minu K., Marni E. Harris‐White, Upendra K. Kar, et al.. (2012). Correction: Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer. PLoS ONE. 7(10). 23 indexed citations

14.

Srivastava, Minu K., Li Zhu, Marni E. Harris‐White, et al.. (2012). Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer. PLoS ONE. 7(7). e40677–e40677. 177 indexed citations

15.

Kar, Upendra K., Janina Jiang, Cheryl I. Champion, et al.. (2012). Vault Nanocapsules as Adjuvants Favor Cell-Mediated over Antibody-Mediated Immune Responses following Immunization of Mice. PLoS ONE. 7(7). e38553–e38553. 36 indexed citations

16.

Gabbita, S. Prasad, Minu K. Srivastava, Pirooz Eslami, et al.. (2012). Early intervention with a small molecule inhibitor for tumor nefosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease. Journal of Neuroinflammation. 9(1). 99–99. 74 indexed citations

17.

Haile, Samuel, et al.. (2011). Tumor cell Programmed Death Ligand-1-mediated T cell suppression is overcome by co-expression of CD80 (66.29). The Journal of Immunology. 186(1_Supplement). 66.29–66.29. 1 indexed citations

18.

Srivastava, Minu K., Pratima Sinha, Virginia K. Clements, Paulo C. Rodrı́guez, & Suzanne Ostrand‐Rosenberg. (2009). Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. Cancer Research. 70(1). 68–77. 759 indexed citations breakdown →

19.

Srivastava, Minu K., Jacobus J. Bosch, James A. Thompson, et al.. (2008). Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunology Immunotherapy. 57(10). 1493–1504. 82 indexed citations

20.

Li, Xiang, et al.. (2007). The reverse in-gel kinase assay to profile physiological kinase substrates. Nature Methods. 4(11). 957–962. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact